Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment

Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells

(2020) Sanjay Varikuti et al.   BRITISH JOURNAL OF CANCER

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China

(2020) Dawei Wang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

(2020) Michael Overman et al.   Journal for ImmunoTherapy of Cancer

Second generation BTK inhibitors impair the anti‐fungal response of macrophages and neutrophils

(2020) Ana Colado et al.   AMERICAN JOURNAL OF HEMATOLOGY

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

(2020) Steven P. Treon et al.   BLOOD

BTK inhibitors in cancer patients with COVID19: "The winner will be the one who controls that chaos" (Napoleon Bonaparte)

(2020) Elise A. Chong et al.   CLINICAL CANCER RESEARCH

Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1β–mediated colitis

(2020) Liming Mao et al.   JOURNAL OF CLINICAL INVESTIGATION

A pilot study of Bruton’s tyrosine kinase inhibitor ibrutinib alone and in combination with PD-1 inhibitor nivolumab in patients with metastatic solid tumors.

(2020) Brooke Benner et al.   JOURNAL OF CLINICAL ONCOLOGY

Covid-19 in Critically Ill Patients in the Seattle Region — Case Series

(2020) Pavan K. Bhatraju et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

(2020) Mark Roschewski et al.   Science Immunology

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia

(2019) Alexander P. de Porto et al.   MOLECULAR MEDICINE

Inhibition of Bruton’s Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer’s Disease

(2019) James Keaney et al.   Journal of Neuroimmune Pharmacology

Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy

(2019) Qiujun Qiu et al.   Acta Biomaterialia

Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma

(2019) C. Owen et al.   Current Oncology

T-cell expression of Bruton’s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia

(2019) Simo Xia et al.   Cellular & Molecular Immunology

Effects of BTK signalling in pathogenic microorganism infections

(2019) Bingjue Ye et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Evidence for interaction of the NLRP3 inflammasome and Bruton’s tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta

(2019) Brooke Benner et al.   OncoImmunology

Inhibiting Bruton’s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury

(2018) Jon M. Florence et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis

(2018) Amelia Bercusson et al.   BLOOD

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function

(2018) Andrew Stiff et al.   CLINICAL CANCER RESEARCH

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

(2018) Michael Wang et al.   LANCET

Role of Bruton’s tyrosine kinase in B cells and malignancies

(2018) Simar Pal Singh et al.   Molecular Cancer

Bruton’s Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus

(2018) Anne B. Satterthwaite   Frontiers in Immunology

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis

(2018) Ana Colado et al.   Blood Cancer Journal

Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase

(2017) Xiao Liu et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Tumor-associated macrophages: from basic research to clinical application

(2017) Li Yang et al.   Journal of Hematology & Oncology

Study of the NLRP3 inflammasome component genes and downstream cytokines in patients with type 2 diabetes mellitus with carotid atherosclerosis

(2017) Junli Lee et al.   Lipids in Health and Disease

The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages

(2017) Lingyan Ping et al.   Oncotarget

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment

(2016) Andrew Stiff et al.   CANCER RESEARCH

Btk inhibition treats TLR7/IFN driven murine lupus

(2016) Andrew T. Bender et al.   CLINICAL IMMUNOLOGY

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

(2016) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma

(2015) D. Masso-Valles et al.   CANCER RESEARCH

Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus

(2015) S. Herbst et al.   EMBO Molecular Medicine

Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury

(2015) Minako Ito et al.   Nature Communications

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer

(2015) A. J. Gunderson et al.   Cancer Discovery

Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients

(2015) Caroline Bergenfelz et al.   PLoS One

Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma

(2015) Laura Soucek et al.   NEOPLASIA

Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants

(2014) Linda M Hartkamp et al.   ANNALS OF THE RHEUMATIC DISEASES

Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

(2014) S. E. M. Herman et al.   BLOOD

Knockdown of Burton’s tyrosine kinase confers potent protection against sepsis-induced acute lung injury

(2014) Panyu Zhou et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells

(2014) Vaclav Seda et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells

(2014) Nicole Grabinski et al.   INVESTIGATIONAL NEW DRUGS

Dual Functions of Bruton's Tyrosine Kinase and Tec Kinase during Fc  Receptor-Induced Signaling and Phagocytosis

(2014) J. Jongstra-Bilen et al.   JOURNAL OF IMMUNOLOGY

Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer

(2014) Jinpu Yu et al.   JOURNAL OF IMMUNOLOGY

Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells

(2014) Wen Gao et al.   JNCI-Journal of the National Cancer Institute

National Trends in Patient Safety for Four Common Conditions, 2005–2011

(2014) Yun Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pancreatic Ductal Adenocarcinoma Contains an Effector and Regulatory Immune Cell Infiltrate that Is Altered by Multimodal Neoadjuvant Treatment

(2014) Kendall C. Shibuya et al.   PLoS One

The Non-receptor Tyrosine Kinase Tec Controls Assembly and Activity of the Noncanonical Caspase-8 Inflammasome

(2014) Florian Zwolanek et al.   PLoS Pathogens

The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss

(2013) Masahiro Shinohara et al.   BONE

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells

(2013) B. Weide et al.   CLINICAL CANCER RESEARCH

Ibrutinib and novel BTK inhibitors in clinical development

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

The Tyrosine Kinase Btk Regulates the Macrophage Response to Listeria monocytogenes Infection

(2013) Afitap Derya Köprülü et al.   PLoS One

X-Linked Immunodeficient Mice Exhibit Enhanced Susceptibility to Cryptococcus neoformans Infection

(2013) W. A. Szymczak et al.   mBio

Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials

(2013) Jan A. Burger   Current Hematologic Malignancy Reports

Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages

(2013) Karin Strijbis et al.   PLoS Pathogens

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

(2012) A. Wiestner   BLOOD

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

(2012) Y.-T. Tai et al.   BLOOD

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

(2012) M. F. M. de Rooij et al.   BLOOD

Tyrosine Kinase Btk Is Required for NK Cell Activation

(2012) Yan Bao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Structure of the chemokine receptor CXCR1 in phospholipid bilayers

(2012) Sang Ho Park et al.   NATURE

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

(2012) Marcus Dühren-von Minden et al.   NATURE

Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response

(2012) K.-G. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TEC family kinases in health and disease - loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK

(2011) Alamdar Hussain et al.   FEBS Journal

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk

(2011) Xingguang Liu et al.   NATURE IMMUNOLOGY

Ischemia and reperfusion—from mechanism to translation

(2011) Holger K Eltzschig et al.   NATURE MEDICINE

The immunology of stroke: from mechanisms to translation

(2011) Costantino Iadecola et al.   NATURE MEDICINE

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

(2011) Betty Y Chang et al.   ARTHRITIS RESEARCH & THERAPY

TLR signaling and effector functions are intact in XLA neutrophils

(2010) Thomas U. Marron et al.   CLINICAL IMMUNOLOGY

Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells

(2010) M. G. Lechner et al.   JOURNAL OF IMMUNOLOGY

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Role of BTK in TLR Signaling

(2009) T.U. Marron   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Fine-tuning of GPCR activity by receptor-interacting proteins

(2009) Stefanie L. Ritter et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals

(2008) Masahiro Shinohara et al.   CELL